Authors
Latest:
Dr. Tsimberidou on the Next Steps for Personalized CareDr. Apostolia Tsimberidou from MD Anderson Cancer Center on the Next Steps for Personalized Care
Latest:
Primary Radiation Therapy for Myeloid Sarcoma of the Porta HepatisTreating myeloid sarcoma at the porta hepatis with 24 Gy over 12 fractions is a well-tolerated treatment that achieved a complete, durable response with minimal toxicity.
Latest:
Impact of BTK Inhibition on Monocytic Myeloid-Derived Suppressor Cells in CLLArantxa Romero-Toledo, PhD student, at the Centre for Haemato-Oncology, Barts Cancer Institute, discusses the impact of BTK inhibition on monocytic myeloid-derived suppressor cells (MDSCs) in chronic lymphocytic leukemia (CLL).
Latest:
Dr El-Jawahri on the Benefits of Earlier Palliative Care in Hematologic MalignanciesAreej El-Jawahri, MD, discusses the potential benefits of earlier palliative care for patients with hematologic malignancies.
Latest:
Dr. Al-Kali on FDA Approval of Inotuzumab Ozagamicin in ALLAref Al-Kali, MD, hematologist, oncologist, Mayo Clinic, discusses the FDA approval of inotuzumab ozagamicin for the treatment of patients with acute lymphoblastic leukemia (ALL).
Latest:
Dr. Melnick on Targeting EZH2 in DLBCLAri Melnick, MD, a professor of medicine at the Weill Cornell Medical College, discusses EZH2 and its potential as a target in diffuse large B-cell lymphoma.
Latest:
Dr. VanderWalde on the Clinical Implications of IMpower150 and KEYNOTE-021Ari VanderWalde, MD, MPH, director, West Cancer Center, assistant professor, Division of Hematology/Oncology, the University of Tennessee Health Science Center, discusses the design of the IMpower150 and KEYNOTE-021 trials.
Latest:
Dr. Zimran Discusses Gaucher Disease BiomarkersDr. Ari Zimran, from Shaare Zedek Medical Center, Jerusalem, Discusses Biomarkers in Gaucher Disease
Latest:
Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter ValidationRapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.
Latest:
Changes in Prostate Cancer Presentation for Radiation Oncology CareUSPSTF guidelines may have decreased the number of patients presenting with prostate cancer for radiation oncology care, particularly those with low-risk disease, without a short-term increase in higher-risk disease.
Latest:
Dr. Perry on Implications of WHO Tumor Classifications in Brain CancerArie Perry, MD, chief of Neuropathology, University of California, San Francisco, discusses the potential implications of the new World Health Organization central nervous system tumor classifications.
Latest:
Radiotherapy in the Modern Era in the Management of Langerhans Cell HistiocytosisIntensity-modulated radiotherapy reduces the mean radiation dose delivered to critical normal structures and should be considered in Langerhans cell histiocytosis treatment when radiotherapy is indicated, particularly given the expected, long-term survival of these patients.
Latest:
An Explorer's Mentality Leads to Novel Treatments in Prostate and Bladder CancerAlthough he held a longtime fascination with space exploration to the moon and Mars, Daniel P. Petrylak, MD, took a different path and broke new ground in another frontier: genitourinary oncology.
Latest:
Dr. Noy on Next Phase of a Trial With Devimistat in Relapsed/Refractory Burkitt LymphomaAriela Noy, MD, discusses the next phase of a trial with devimistat in patients with relapsed/refractory Burkitt lymphoma.
Latest:
RET Inhibitor Tested in Multiple Tumor TypesInvestigators are evaluating the potential of LOXO-292, an oral small molecule inhibitor of RET signaling, to improve outcomes in patients with RET fusion–positive non–small cell lung cancer, medullary thyroid cancer, and other tumors.
Latest:
Dr. Balar on Results of KEYNOTE-052 in Urothelial CancerArjun Balar, MD, director, Genitourinary Medical Oncology Progam, NYU Langone Medical Center, discusses the results from the KEYNOTE-053 trial in cisplatin-ineligible advanced urothelial carcinoma.
Latest:
The Patient Is Ready, But the Insurance Is NotTo provide the best care for the patients in front of us, oncologists must once again go above and beyond as needed.
Latest:
Dr. Balar on Next Steps of the KEYNOTE-057 Trial in NMIBCArjun V. Balar, MD, director, Genitourinary Medical Oncology Program, assistant professor, Department of Medicine, NYU Langone's Perlmutter Cancer Center, discusses the next steps for research regarding the phase II KEYNOTE-057 trial in nonmuscle–invasive bladder cancer (NMIBC).
Latest:
Molecularly Targeted Therapy and Immunotherapy: The Next Frontier in Metastatic Bladder CancerA major step toward improved tolerability of cisplatin-based therapy came in the early 2000s with the advent of the modern regimen of gemcitabine and cisplatin.
Latest:
Dr. Chan on ExteNET Trial for HER2+ Breast CancerArlene Chan, MD, director, Mount Hospital at Perth, discusses the ExteNET trial, which looked at neratinib as extended adjuvant therapy in patients with early-stage HER2-positive breast cancer.
Latest:
Dr Siefker-Radtke on the Safety of Enfortumab Vedotin Plus Pembrolizumab in Bladder CancerArlene O. Siefker-Radtke, MD, discusses toxicities associated with enfortumab vedotin plus pembrolizumab in patients with bladder cancer.
Latest:
Tissue and Liquid Biopsies in Metastatic Urothelial CancerA discussion on current prognostic and predictive testing assays used to detect FGFR mutations in patients with metastatic urothelial cancer (mUC).
Latest:
Dr. Arlene Sharpe on the Role of the PD-1 PathwayArlene Sharpe, MD, PhD, immunology faculty member, Harvard Medical School, discusses the biology of the PD-1 pathway.
Latest:
On the Horizon: Exciting Prospects in the Acute Lymphoblastic Leukemia Treatment LandscapeClosing thoughts from a panel of ALL experts on improving access to therapy and how their field may evolve in years to come.
Latest:
Optimizing Precision Medicine in HCCTakeaways from a discussion on treatment advances in hepatocellular carcinoma.
Latest:
Camrelizumab Plus Rivoceranib vs Sorafenib as First-Line Therapy for Unresectable Hepatocellular Carcinoma (uHCC): Final Overall Survival Analysis of the Phase 3 CARES-310 StudyThis is a final overall survival analysis on the phase 3 CARES-310 study (NCT03764293), a randomized, open-label, international phase 3 trial comparing camrelizumab plus rivoceranib vs sorafenib as first-line therapy for unresectable hepatocellular carcinoma (uHCC).
